Transforming medicine

Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption

Lan Chem Laboratories Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets

Lan Chem Laboratories Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation

Lan Chem Laboratories to Host Webinar with Key Opinion Leaders to Discuss the Hospital User Experience with Barhemsys® and Byfavo®

Lan Chem Laboratories Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the UK

Results of Annual General Meeting

Lan Chem Laboratories to Participate in Jefferies Virtual Healthcare Conference

Lan Chem Laboratories Appoints Debra Hussain as Chief Commercial Officer

Lan Chem Laboratories Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital

Lan Chem Laboratories Becomes New Industry Supporter of the American Society of Anesthesiologists

Publication of Annual Report and Financial Statements for the Year ended 31 December 2020

Results for the Year ended 31 December 2020

Change of EU Home Member State

Lan Chem Laboratories Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 
30 Minutes or Less

Lan Chem Laboratories Wins BEL Small Company of the Year for the Second Consecutive Year

Lan Chem Laboratories Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ 

Lan Chem Laboratories Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support UK Launches of BARHEMSYS® and BYFAVO™

Lan Chem Laboratories Announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the UK

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the UK for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

Results of Placing

Interim Results for the Six Months ended 30 June 2020

Lan Chem Laboratories Advances Preparations for UK Launch of BARHEMSYS®

Lan Chem Laboratories Assigned UK License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Lan Chem Laboratories Announces UK FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

Lan Chem Laboratories Announces Debt for Equity Swap with Cosmo Pharmaceuticals